Semaglutide

Summary

• Semaglutide reduces body weight by roughly 15 percent over 68 weeks at 2.4 mg weekly, against 2.4 percent on placebo. It is the most consistently reproduced result on this page, replicated across the STEP program.1

• The 2025 Cochrane review, funded by the World Health Organization, rated the weight loss evidence high certainty and the cardiovascular and mortality evidence low to moderate certainty.6

• Maintaining the weight loss requires continuing treatment. One year after stopping, participants regained roughly two thirds of the weight lost, leaving a net 5.6 percent below where they started.3

• Tirzepatide produced greater weight loss in a direct comparison, 20.2 percent against 13.7 percent.14

• Muscle loss is real but proportionally small. Lean mass accounted for under 20 percent of total weight lost.23

• Gastrointestinal side effects are very common, affecting 49 to 71 percent of participants depending on trial and dose, against 26 to 43 percent on placebo. They are the most commonly cited reason for stopping, though only 4.5 percent of STEP 1 participants discontinued because of them.1,2,4

• A signal linking semaglutide to nonarteritic anterior ischemic optic neuropathy has appeared across multiple studies. Absolute risk is low and the question is unresolved.20,21

• Real-world weight loss is lower than trial weight loss, mostly because 20 to 50 percent of people stop within the first year and many never reach trial doses.27

Basics and Mechanism

What Is Semaglutide?

Semaglutide is a modified copy of GLP-1, a hormone the gut releases after a meal. Natural GLP-1 breaks down within minutes. Semaglutide resists that breakdown, which is why a single injection lasts a week.

It is sold under three brand names for two purposes. Ozempic and Rybelsus treat type 2 diabetes. Wegovy treats obesity.

How Does Semaglutide Work?

Semaglutide binds the GLP-1 receptor. Four consequences matter. It prompts insulin release when blood glucose is high. It slows the rate at which the stomach empties. It acts on appetite signaling in the brain, reducing food intake. A 2026 review in Nature Medicine adds that some benefit appears to come from direct receptor activation in tissues beyond the gut and pancreas, and from reduced inflammation, rather than from weight loss alone.16

That last point is not settled. It is one explanation offered for why cardiovascular and kidney benefits appear larger than weight loss alone would predict, and the review advances it as a mechanism rather than a demonstrated cause.

Is Semaglutide the Same as Ozempic?

Semaglutide is the drug. Ozempic is one brand name for it.

The three brands differ by dose, route and approved use. Ozempic is a weekly injection approved for type 2 diabetes. Rybelsus is a daily tablet approved for type 2 diabetes. Wegovy is a weekly injection with the broadest set of approved uses.

Wegovy is approved for weight reduction and long-term weight maintenance, for reducing cardiovascular risk, and for metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis, approved 15 August 2025. The maximum weight-management dose is 7.2 mg weekly, approved on 19 March 2026 as Wegovy HD for adults who tolerate 2.4 mg.45,46

Is Semaglutide Insulin?

No. Insulin lowers blood glucose directly. Semaglutide prompts the pancreas to release its own insulin, and only when blood glucose is already elevated. This difference is why semaglutide alone carries a low hypoglycemia risk while insulin carries a high one.

Dosing as Studied

The schedules below are taken from published trial protocols. They are a record of what was tested, not a prescription.

What Dose Schedule Was Used in the Weight Loss Trials?

Escalation is gradual in every published protocol. The steps exist to limit gastrointestinal side effects, which cluster during dose increases.

Why Do Different Trials Use Different Doses?

Dose tracks the outcome being tested, not the size of the person. FLOW, which tested kidney outcomes, and STRIDE, which tested walking distance, both used 1.0 mg weekly.8,11 SELECT and ESSENCE used 2.4 mg.7,10 SOUL used oral semaglutide at a maximum of 14 mg daily.9

Is There a Dose Above 2.4 mg?

Yes, and it is now approved. STEP UP randomized 1,407 adults to semaglutide 7.2 mg, 2.4 mg or placebo for 72 weeks. Weight fell 18.7 percent on 7.2 mg against 15.6 percent on 2.4 mg, a difference of 3.1 percentage points.4

Side effects rose with the dose. Gastrointestinal events affected 70.8 percent on 7.2 mg against 61.2 percent on 2.4 mg. Altered skin sensation was reported by 22.9 percent on 7.2 mg against 0.5 percent on placebo.4

One trial is a narrow base for a dose, and the extra 3.1 percentage points came with a measurably worse side effect profile. The FDA approved the dose anyway, as Wegovy HD on 19 March 2026, 54 days after filing under the Commissioner's National Priority Voucher pilot program.45

The agency's own announcement flags the skin finding. Altered skin sensation, described as sensitivity, pain or burning, was common, occurred more frequently at the higher dose, and generally resolved on its own or with dose reduction. The FDA states it is currently conducting further investigations into that reaction.45

Does Body Weight Change the Dose?

Published protocols do not adjust dose by body weight. Every STEP trial used the same fixed titration schedule regardless of starting weight.

Oral Semaglutide

Does the Tablet Work as Well as the Injection?

The two forms have not been compared head-to-head in a completed outcome trial at equivalent obesity doses. A 2026 analysis used population pharmacokinetics and exposure-response modeling to extrapolate the efficacy of oral semaglutide 25 mg against subcutaneous 2.4 mg, an approach used to satisfy regulatory requirements rather than to replace a direct trial.18

For cardiovascular outcomes, the oral form has its own trial. SOUL followed 9,650 people with type 2 diabetes and established artery or kidney disease for a mean of 47.5 months. Major cardiovascular events occurred in 12.0 percent on oral semaglutide against 13.8 percent on placebo.9 OASIS 2 tested oral semaglutide for weight in an East Asian population.19

Why Does the Tablet Have to Be Taken on an Empty Stomach?

Peptides are poorly absorbed from the gut. The oral formulation includes an absorption enhancer, and food in the stomach interferes with that process. This is why the approved oral dose is far higher than the injected dose. It compensates for low absorption rather than delivering more drug to the bloodstream.

What to Expect Over Time

How Fast Does Weight Come Off?

Weight loss in the STEP trials was progressive across 68 weeks rather than front-loaded. In STEP 1, the mean change at week 68 was 14.9 percent, and the curve had not fully flattened.1 In STEP 4, participants lost a mean of 10.6 percent during a 20-week run-in, then continued losing for a further 48 weeks on treatment.2

How Many People Respond?

In STEP 1, at week 68: 86.4 percent lost at least 5 percent of body weight, 69.1 percent lost at least 10 percent, and 50.5 percent lost at least 15 percent. Placebo figures were 31.5 percent, 12.0 percent, and 4.9 percent.1

Roughly one in seven participants did not reach 5 percent loss despite completing treatment.

Why Is Real-World Weight Loss Lower Than Trial Weight Loss?

A 2025 review of real-world evidence identified three drivers. Weight reduction in practice tends to be lower than in randomized trials. Between 20 and 50 percent of people discontinue within the first year. Many use doses well below those tested in trials.27

The same review found that outcomes approach trial results among highly adherent patients. The gap is largely one of dose reached and duration sustained, not a different drug effect.

What Does a Plateau Mean?

Trial data do not define a plateau threshold, and no published trial has tested a protocol for breaking one. Weight loss curves in the STEP program continued for the full trial duration at maintenance dose, so a plateau before the maintenance dose is reached is a different situation from a plateau after 68 weeks at 2.4 mg.

This is a genuine evidence gap, and it is the highest-demand unanswered question in the field.

Stopping, Maintenance and Rebound

What Happens If Treatment Stops?

An extension of STEP 1 followed 327 participants for one year after treatment ended. They had lost 17.3 percent of body weight. They regained 11.6 percentage points of it, leaving a net loss of 5.6 percent. Improvements in blood pressure, lipids and blood glucose drifted back toward baseline.3

Placebo participants regained 1.9 percentage points over the same window. A 2025 narrative review of randomized studies found the same pattern across the drug class.28

What Happens If Treatment Continues Instead?

STEP 4 answers this directly. After a 20-week run-in during which all 902 participants received semaglutide, 803 were randomized either to continue at 2.4 mg or to switch to placebo for 48 weeks.

Those who continued lost a further 7.9 percent. Those switched to placebo gained 6.9 percent. The difference between the two paths was 14.8 percentage points.2 Waist circumference, systolic blood pressure and physical function all favored continuation.

Is There a Published Taper Protocol?

No. No trial has tested gradual dose reduction against abrupt discontinuation. STEP 4 tested continuation against a full switch to placebo, and the STEP 1 extension observed abrupt withdrawal. Anything between those two is unstudied.

Gastrointestinal Side Effects

How Common Are They?

Very common, and dose dependent. In STEP UP, gastrointestinal events affected 70.8 percent of participants on 7.2 mg, 61.2 percent on 2.4 mg, and 42.8 percent on placebo.4 In STEP 4, they affected 49.1 percent on continued semaglutide against 26.1 percent on placebo.2 In STEP TEENS, 62 percent against 42 percent.5

The placebo rates matter. A substantial share of reported nausea in these trials occurs without the drug.

Do They Improve Over Time?

In STEP 1 the most common events, nausea and diarrhoea, were described as typically transient and mild to moderate, subsiding with time.1 They cluster during dose escalation, which is why every protocol escalates slowly.

How Often Do They Cause People to Stop?

In STEP 1, 4.5 percent of participants discontinued because of gastrointestinal events, against 0.8 percent on placebo.1 In STEP 9, adverse events led to permanent discontinuation in 6.7 percent against 3.0 percent, with gastrointestinal disorders the most common reason.13

Does Semaglutide Cause Gastroparesis?

Delayed gastric emptying is a mechanism of the drug rather than a side effect in the usual sense. It is part of how food intake is reduced.

The clinical concern is retained stomach contents during procedures requiring sedation. A 2024 retrospective study at a large tertiary center examined this in an ambulatory endoscopy population, noting that GLP-1 receptor agonists are associated with delayed gastric emptying and may raise aspiration risk from retained gastric contents.25

Whether the drug causes persistent gastroparesis as a distinct diagnosis is not established by trial evidence.

Serious Risks

Eyes and NAION

Nonarteritic anterior ischemic optic neuropathy is a sudden interruption of blood flow to the optic nerve that can cause permanent vision loss.

A 2025 meta-analysis pooled 78 trials and 73,640 participants. It found no increase in eye disorders overall, odds ratio 1.01, and none in diabetic retinopathy, odds ratio 1.04. For NAION it found an odds ratio of 3.92 with a confidence interval running from 1.02 to 15.02. The authors stated that the pooled sample was not large enough to settle the question.20

A 2026 study of 102,361 US veterans compared 11,478 people starting semaglutide against 90,883 starting an SGLT2 inhibitor. NAION occurred at 123 cases per 100,000 person-years against 67, a hazard ratio of 2.33. In absolute terms, the weighted incidence was 0.29 percent against 0.13 percent, a difference of 0.16 percentage points.21

The direction is consistent across studies. The absolute risk is small. Neither statement cancels the other.

Thyroid

Rodent studies showing C-cell hyperplasia are the origin of the thyroid warning. Human evidence has not reproduced a cancer signal.

A 2026 systematic review covering six studies and 900,225 participants found no increased risk of thyroid tumors or thyroid cancer in the large cohort studies. Only one of the six directly measured thyroid function, reporting a mild decrease in free thyroxine and slight nodule progression at 12 months, while a Mendelian randomization analysis within that study found no significant causal effect.22

The review's stated purpose was to characterize an evidence gap rather than close one. Systematic thyroid function measurement is absent from the major trials.

Pancreas

A 2026 multicenter analysis concluded that GLP-1 receptor agonist use does not increase the risk of acute pancreatitis in type 2 diabetes, and was associated with lower complications among those who did develop it.24 The 2025 real-world evidence review reached a consistent conclusion.27

Gallbladder

Rapid weight loss of any cause raises gallstone risk. In STEP TEENS, five participants in the semaglutide group, 4 percent, developed cholelithiasis, against none on placebo.5

Serious Adverse Events Overall

Cochrane rated the effect on serious adverse events at medium-term follow-up as very uncertain, risk ratio 1.01. At long-term follow-up it found likely little to no difference, risk ratio 0.92.6

In SOUL, serious adverse events occurred in 47.9 percent on oral semaglutide against 50.3 percent on placebo.9 In FLOW, 49.6 percent against 53.8 percent.8 In both, the treated group had fewer.

Mental Health

Does Semaglutide Increase Suicide Risk?

A 2025 systematic review examined 16 studies published between 2017 and 2024, comprising five observational studies, two randomized trials, eight pharmacovigilance analyses and one post-hoc analysis.

It found no consistent evidence of increased suicide risk. Pharmacovigilance analyses produced mixed results, with some disproportionality signals but no confirmed causal link. Cohort studies in diabetic and obese populations generally showed no significant increase.26 The 2025 real-world review reached the same conclusion.27

The regulator has since acted on a much larger dataset. On 13 January 2026 the FDA requested that manufacturers remove the suicidal ideation and behavior warning from the labeling of Saxenda, Wegovy and Zepbound, after a review that found no increased risk.47

Two analyses sit behind that decision. A meta-analysis of 91 placebo-controlled trials covering 107,910 patients, 60,338 on a GLP-1 receptor agonist and 47,572 on placebo, found no increased risk of suicidal ideation or behavior and none for anxiety, depression, irritability or psychosis. A retrospective cohort study using the FDA Sentinel System compared 1,161,983 people starting a GLP-1 receptor agonist against 1,081,155 starting an SGLT2 inhibitor across 10 data partners, and found no increased risk of intentional self-harm.47

That is a far larger evidence base than the published reviews above, and it moves this question from unresolved to answered for suicidal ideation and behavior specifically. It says nothing about the separate question of anhedonia or loss of enjoyment, which no trial has measured.

Is Losing Enjoyment of Eating a Side Effect, or Just What Restriction Feels Like?

No trial has separated these. Quality of life was measured in the pooled evidence, where Cochrane found likely little to no difference on the SF-36 physical functioning score, rated moderate certainty.6 That instrument was not designed to detect loss of pleasure in eating, and no trial used a measure that was.

The distinction matters because the two have different implications. Reduced food reward is close to the intended mechanism, since the drug acts on appetite signaling in the brain.16 Anhedonia extending beyond food is a different phenomenon and is not something the trials looked for.

Anyone experiencing loss of enjoyment that reaches beyond eating has no trial evidence to consult and should raise it with a clinician rather than wait it out.

How Quickly Does the Desire to Drink Change?

The one randomized trial to measure this ran for nine weeks at doses below those used for weight loss. Weekly alcohol craving fell over that period, as did drinks per drinking day, while the number of drinking days did not change.40

The trial reported outcomes over the treatment period rather than identifying a point at which craving changed, so it does not answer how quickly. Forty-eight participants over nine weeks is a starting point, and the authors described it as justifying larger trials.40

Is Anhedonia a Reason to Switch Molecule Rather Than Stop?

No trial has compared GLP-1 medicines against each other on any psychiatric outcome. Switching to address a mood effect has not been studied, so there is no evidence that a different molecule behaves differently.

The head-to-head trial that exists compared semaglutide and tirzepatide on weight and waist circumference, not on mood.14

Body Composition and Muscle

How Much Muscle Is Lost?

A 2025 meta-analysis pooled 38 publications covering 1,735 participants and separated results by diabetes status.

In people without diabetes, muscle mass measures fell by 1.41 kg while fat mass fell by 6.02 kg. In people with type 2 diabetes, the muscle reduction of 0.74 kg was not statistically significant, while fat mass fell by 3.18 kg. 23

In both groups, the reduction in muscle mass accounted for less than 20 percent of total weight reduction.

Is That Worse Than Dieting?

The meta-analysis did not compare against diet-induced weight loss, and its authors called for further analysis of functional skeletal muscle rather than mass alone. Mass and function are different measures, and the trials measured mass. This is a partial answer, not a complete one.

Comparisons

Semaglutide Against Tirzepatide

SURMOUNT-5 randomized 751 adults with obesity and without diabetes to the maximum tolerated dose of either drug for 72 weeks, open-label.

Tirzepatide produced 20.2 percent weight loss against 13.7 percent for semaglutide. Waist circumference fell 18.4 cm against 13.0 cm. Participants on tirzepatide were more likely to reach every weight loss threshold tested. Gastrointestinal events were the most common adverse events in both groups.14

A 2026 Bayesian network meta-analysis compared tirzepatide, liraglutide and semaglutide in patients with obesity and without type 2 diabetes.15

Semaglutide Against Placebo Across All Trials

Cochrane's pooled estimate at six to seventeen months was a 10.73 percentage point greater reduction in body weight than placebo, rated high certainty. The proportion achieving at least 5 percent loss was 2.68 times higher, also high certainty.6

Outcomes Beyond Weight

Cardiovascular

SELECT enrolled 17,604 patients aged 45 or older with existing cardiovascular disease, a BMI of 27 or above, and no diabetes. Over a mean 39.8 months, cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5 percent on semaglutide against 8.0 percent on placebo, a hazard ratio of 0.80.7

Discontinuation because of adverse events was twice as common on the drug, 16.6 percent against 8.2 percent.

Cochrane is more conservative than the individual trial. Its pooled cardiovascular estimate was rated low certainty at medium term and moderate at long term, and the reviewers described the effect as likely limited or uncertain.6

Kidney

FLOW enrolled 3,533 people with type 2 diabetes and chronic kidney disease and was stopped early on a planned interim analysis. Major kidney events fell 24 percent. Kidney function declined more slowly, with the annual eGFR slope 1.16 ml per minute per 1.73 m2 less steep. Cardiovascular death fell 29 percent and death from any cause fell 20 percent.8

Liver

ESSENCE enrolled 1,197 patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stage 2 or 3. At a planned 72-week interim analysis of the first 800 patients, steatohepatitis resolved without worsening fibrosis in 62.9 percent against 34.3 percent on placebo. Fibrosis improved without worsening steatohepatitis in 36.8 percent against 22.4 percent.10

The trial is designed to run 240 weeks. What is published is an interim result. A 2025 Nature Medicine analysis examined the metabolic, inflammatory and fibrotic pathways involved.17

Knee Osteoarthritis

STEP 9 enrolled 407 participants with obesity and moderate knee osteoarthritis with at least moderate pain. Over 68 weeks, the WOMAC pain score fell 41.7 points against 27.5 on placebo, and physical function improved more on the drug.13

Peripheral Artery Disease

STRIDE enrolled 792 people with type 2 diabetes and peripheral artery disease causing walking pain. Maximum treadmill walking distance improved by a ratio of 1.13 against placebo over 52 weeks.11 The trial did not include people without diabetes.

Heart Failure

STEP-HFpEF DM examined semaglutide 2.4 mg in obesity-related heart failure with preserved ejection fraction alongside type 2 diabetes, with a prespecified analysis across baseline HbA1c published in 2025.12

Special Populations

Adolescents

STEP TEENS randomized 201 participants aged 12 to under 18 with obesity to semaglutide 2.4 mg or placebo for 68 weeks. BMI fell 16.1 percent against a 0.6 percent rise on placebo. Weight loss of at least 5 percent occurred in 73 percent against 18 percent.5

Gastrointestinal adverse events were more common on the drug, 62 percent against 42 percent, and five participants developed gallstones.

Hypothalamic Obesity

A 2026 French multicenter study followed 116 adults with obesity following craniopharyngioma across 16 centers for a mean of 44 months. Mean weight loss was 4.6 percent, far below trial figures, with wide variation between individuals. Semaglutide at a mean dose of 1.2 mg weekly produced the largest reduction at 6.8 percent.29

Endocrine adverse events were notable in this group. Adrenal decompensation occurred in 12 percent and vasopressin deficiency decompensation in 10 percent, with 8 percent requiring hospitalization.

This is the clearest published example of a population in which trial figures do not transfer.

Shift Work

No trial has examined whether working nights changes the response to semaglutide. Dosing is weekly rather than tied to time of day, which limits the mechanisms by which shift timing could matter, but this has not been tested.

Losing More Weight Than Intended

No trial has studied overshooting, because trials enrol people to lose weight and stop at a fixed endpoint. There is no published protocol for reducing or stopping treatment once a target is passed, and no data on what happens to weight afterwards other than the withdrawal findings above.

Women’s Health

Does Semaglutide Affect the Menstrual Cycle?

In women with polycystic ovary syndrome, yes, and the direction is toward regularity. A 2026 systematic review reports that clinical trials of GLP-1 receptor agonists in overweight and obese women with PCOS showed improved menstrual regularity, reduced body weight and central adiposity, increased sex hormone-binding globulin and lower free testosterone.42

A 2026 narrative review reaches a consistent conclusion, that these drugs may improve ovulatory function and menstrual regularity, particularly in women with obesity or PCOS.41

Outside PCOS, the evidence is much thinner. Most trials did not measure menstrual outcomes at all.

Can Cycle Changes Happen Before Much Weight Is Lost?

Mechanistically, this is possible. The 2026 systematic review describes GLP-1 receptor signaling acting directly on ovarian physiology, affecting granulosa cell proliferation, survival pathways and steroidogenesis, alongside the systemic metabolic effects.42 Effects that do not depend on weight loss would not have to wait for weight loss.

No trial has been designed to establish the timing, so this remains a mechanism that could explain the observation rather than a demonstrated one.

Unexpected Bleeding, Spotting and Heavy Bleeding

There is no published clinical literature specifically examining intermenstrual bleeding, spotting or heavy bleeding with semaglutide. Targeted searching of the indexed literature returns nothing on this question.

The nearest relevant finding is preclinical and should not be read as an explanation. Animal studies in the 2026 systematic review produced results in both directions, including beneficial effects on follicular growth and detrimental ones including oxidative stress, granulosa cell death and uterine inflammation, described as context and dose-dependent. The reviewers noted that while preliminary clinical data indicate improved reproductive function in PCOS, animal studies reveal a potential risk of ovarian and endometrial damage, and called for controlled human research.42

That is animal data. It does not establish that semaglutide causes bleeding in humans, and it is not a reason to attribute bleeding to the drug.

Bleeding after menopause is a red flag

Any vaginal bleeding after menopause requires medical assessment, regardless of what medication a person is taking. This is standard gynaecological practice because post-menopausal bleeding can indicate endometrial pathology, and the assessment exists to rule that out.

Starting a GLP-1 medicine does not change that. Attributing post-menopausal bleeding to a drug without assessment risks delaying a diagnosis, and there is no published evidence that semaglutide causes it. The same applies to bleeding heavy enough to prompt consideration of hysteroscopy or dilatation and curettage. These are reasons to be examined, not reasons to search for a drug explanation.

Is There a Difference Between the Injection and the Tablet?

No comparative data exist on bleeding or menstrual outcomes between the injectable and oral formulations. No trial has measured it for either.

Does It Interact with Contraception?

A 2024 systematic review examined co-administered oral drugs including contraceptive pills. Peak concentration was reduced or unchanged and time to peak delayed, consistent with slowed gastric emptying, but overall drug exposure showed no clinically significant change and the reviewers concluded dose adjustments are probably not required.35

The more consequential point is not pharmacokinetic. Because these drugs may improve ovulatory function and increase the likelihood of conception, a 2026 review raises the specific concern of unintended pregnancy, and advises contraceptive counseling alongside prescribing.41 Someone who was not conceiving before may conceive now.

No data exist on intrauterine devices specifically.

Fertility and Conception

The 2026 narrative review concludes that these drugs may improve ovulatory function and menstrual regularity, potentially increasing the likelihood of conception, while noting that human data on pregnancy exposure remain limited.41

On assisted reproduction, the 2026 systematic review reports that liraglutide combined with metformin significantly improved IVF pregnancy rates, and that exenatide increased natural conception rates.42 Both findings concern other drugs in the class rather than semaglutide, and neither establishes what happens after a failed IVF cycle.

Pregnancy

The manufacturer advises stopping Wegovy two months before a planned pregnancy.38

A multicenter prospective observational cohort drawing on six Teratology Information Services assessed reproductive safety of exposure in early pregnancy.30 The 2026 narrative review summarizes the position as no consistent strong teratogenic signal, but based on small samples and heterogeneous study designs, with concerns persisting about the absence of robust safety data during early gestation.41

No randomized trial has studied use during pregnancy, and none is likely to. On use after birth, no trial has examined starting treatment postpartum, whether or not someone is breastfeeding.

PCOS

Covered above under menstrual regularity, which is where the PCOS evidence is strongest. A 2024 meta-analysis of randomized trials also examined GLP-1 receptor agonists in women with PCOS and obesity for weight loss and hormonal measures.31 The pooled trials covered multiple drugs in the class rather than semaglutide alone.

Menopause and Perimenopause

No trial has examined semaglutide specifically for perimenopausal metabolic change, insulin resistance or inflammation in that population.

What can be said is that anti-inflammatory effects of this drug class are an active research area, with a 2025 review describing reductions in systemic and tissue inflammation through both weight-loss-dependent and independent mechanisms.44 That is a general finding about the class, not a menopause finding.

A menstrual period returning after a prolonged absence is a clinical event that warrants assessment on its own terms. No published evidence establishes that semaglutide reverses menopause, and a diagnosis of early menopause that appears to change should be re-examined by the clinician who made it.

Endometriosis

No published trial has examined semaglutide in endometriosis, in either direction.

Off-Label and Emerging Uses

Alzheimer’s Disease

Two phase 3 trials, evoke and evoke+, are testing semaglutide in early-stage symptomatic Alzheimer's disease. Baseline characteristics were published in 2026.32

Baseline characteristics are not results. No efficacy conclusion is available.

What Else Is Being Studied?

A 2026 Nature Medicine review lists active exploration in neurodegenerative disorders, substance use disorders, metabolic liver disease, arthritis, type 1 diabetes and inflammatory bowel disease.16

Exploration is not evidence. Each of these sits at a different stage, and most have no completed phase 3 result.

Other Side Effects

Does Semaglutide Cause Hair Loss?

A 2025 systematic review searched three databases for hair loss associated with GLP-1 receptor agonists. It found five relevant studies covering 2,905 adults, most of whom received tirzepatide rather than semaglutide.

The findings conflicted. Some studies reported hair loss as an adverse dermatological event. Others reported improvement and regrowth. The reviewers concluded that further research is needed to clarify the relationship.33

Two things are worth separating. Rapid weight loss from any cause can trigger telogen effluvium, a temporary shedding phase. That is a known consequence of rapid weight loss rather than a drug-specific effect. Whether semaglutide adds anything beyond that has not been established.

Will Hair Grow Back After the Shedding Phase?

Telogen effluvium, the shedding pattern triggered by rapid weight loss and other physiological stressors, is self-limiting by definition. It reflects hair follicles entering a resting phase together and then shedding together, after which the cycle resumes.

That is general dermatology rather than a semaglutide finding. The systematic review specific to this drug class found conflicting results, with some studies reporting hair loss and others reporting improvement and regrowth, and called for further research.33 No study has followed regrowth in people who shed hair on semaglutide specifically.

Is Persistent Exhaustion a Reason to Stop?

Fatigue is not among the outcomes any of the major trials measured as a discontinuation reason, so there is no evidence on how often it resolves or how often it leads people to stop.

What is known is that discontinuation because of adverse events is roughly twice as common on semaglutide as on placebo across the pooled evidence,6 and that real-world discontinuation runs at 20 to 50 percent in the first year.27 Neither figure identifies which symptom drove the decision.

Persistent exhaustion also has causes worth excluding, including inadequate intake and nutrient deficiency during rapid weight loss, both of which the 2025 joint nutrition advisory names as challenges requiring active management.37

Is There More Risk of Catching a Stomach Bug?

No evidence indicates increased susceptibility to gastrointestinal infection. The trials record gastrointestinal adverse events at high rates, but those are drug effects rather than infections.1,4

The practical difficulty is that the symptoms overlap, so distinguishing a drug effect from an infection is genuinely hard, and no study has looked at how often that confusion occurs.

Can Rapid Weight Loss Cause New Back Pain?

No study has examined new musculoskeletal pain arising during semaglutide treatment.

The one musculoskeletal trial in the program ran in the opposite direction. STEP 9 found knee osteoarthritis pain fell substantially more on semaglutide than placebo over 68 weeks.13 That concerns an existing painful joint under load, not the appearance of new pain elsewhere, and it cannot be extended to the back.

What About Facial Volume Loss and Skin Laxity?

A 2025 review in the aesthetic dermatology literature addressed this directly, noting that rapid weight reduction induced by these medications often leads to aesthetic consequences including facial volume loss, skin laxity and body contour irregularities.34

The mechanism is weight loss speed, not a specific action on facial tissue. Fat is lost from the face as it is lost elsewhere, and skin does not always retract at the same rate. The popular name for this attaches the effect to one brand. The cause is the rate of loss.

Drug Interactions

Does Semaglutide Interfere with Other Medications?

A 2024 systematic review in Drug Safety examined this specifically. It included 22 reports and six prescribing sheets covering pharmacokinetic studies of injectable GLP-1 receptor agonists given alongside oral drugs.35

The pattern was consistent across drug classes. Peak concentration was unaffected or reduced, and time to peak was delayed, for drugs spanning all four solubility and permeability categories: warfarin, contraceptive pills and acetaminophen; ACE inhibitors; statins; and digoxin.

The clinically important finding is what did not change. Overall drug exposure, measured as area under the curve, showed no clinically significant change, and there were no differences in clinically relevant endpoints. The reviewers concluded that dose adjustments are probably not required for simultaneous use.35

Does That Apply to Everyone?

No, and the reviewers said so. The studies enrolled healthy subjects, and there was insufficient data on conditions that might affect pharmacokinetics such as kidney dysfunction. The reviewers cautioned that results should be generalized carefully to people with background kidney dysfunction or those taking drugs with a narrow therapeutic index.35

What About Lithium?

Lithium is exactly the narrow therapeutic index case the reviewers flagged, and there is now direct evidence.

A 2025 case series described three patients on stable lithium regimens who started semaglutide. In two, lithium levels rose significantly and produced toxicity, despite stable kidney function and no other medication changes. In the third, a preemptive lithium dose reduction limited toxicity, though levels still ran higher than expected.36

The authors proposed altered kidney function, dehydration from reduced oral intake, vomiting or diarrhoea, and delayed gastric emptying as candidate mechanisms. They recommended assessing baseline kidney function, hydration and lithium levels before starting semaglutide, and monitoring lithium more frequently during treatment.36

Three cases is a signal, not a rate. It is enough to warrant monitoring and not enough to quantify risk.

Can Semaglutide Treat Other Conditions I Have?

This question arrives in many forms, and the honest answer is the same for most of them: the condition has not been studied.

A 2025 review does describe reductions in systemic and tissue inflammation through both weight-loss-dependent and independent mechanisms, which is why so many inflammatory conditions are being explored.44 Being explored is not the same as being shown to work.

Does It Affect Cancer Risk?

A 2026 review in Nature Cancer sets out the current position. These drugs reduce food intake, body weight, insulin resistance and inflammation, and may thereby contribute to decreased cancer incidence, with potential for suppression of tumorigenesis and reduction in obesity-associated cancer rates through both weight-loss-dependent and independent mechanisms.43

The data summarized come from trials and registries in people with type 2 diabetes, alongside preclinical models. That is a question about incidence in a treated population. It is not a study of recurrence after a cancer diagnosis, and no such trial has reported.

Can I Stop My Blood Pressure Medication or Statin After Losing Weight?

No trial has tested deprescribing other medicines during or after semaglutide treatment.

What the trials show is that cardiovascular benefit was observed in people taking semaglutide in addition to standard care, not instead of it. SELECT participants remained on their usual treatment.7 Improvements in blood pressure and lipids are recorded as changes on treatment, and the withdrawal data show cardiometabolic measures drifting back toward baseline after stopping.3

Deprescribing is a decision for the prescriber who is monitoring the numbers, and it is not supported or refuted by anything in the semaglutide evidence base.

Do Benefits Fade If a Dose Is Missed?

No trial has measured what happens after a single missed dose. The half-life supports a weekly interval, and the withdrawal studies measured outcomes over months rather than days, so neither answers the question.3,2

Hormone Replacement Therapy

No study has examined whether semaglutide works differently alongside hormone replacement therapy, or whether the type of progesterone used makes a difference. No trial has examined reversal of weight gained after starting hormone therapy.

The general interaction finding applies: oral drug exposure was not clinically significantly altered in the systematic review of co-administered medicines.35 That covers absorption. It does not answer whether the two treatments interact biologically.

Diabetes Medications and Low Blood Sugar

Semaglutide alone carries a low hypoglycemia risk because it prompts insulin release only when glucose is already elevated. Combined with insulin or a sulfonylurea, that changes, and the manufacturer's safety information identifies increased hypoglycemia risk in people also taking those drugs.38

Nutrition, Protein and Supplements

Is There Authoritative Guidance on Eating During Treatment?

Yes, and it is recent. In 2025 four organizations issued a joint advisory: the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society.37

The advisory names the specific problems nutrition has to address during treatment: gastrointestinal side effects, nutritional deficiencies caused by reduced calorie intake, muscle and bone loss, low long-term adherence with subsequent weight regain, and high cost.37

Its stated priorities during treatment are managing gastrointestinal side effects, navigating altered dietary preferences and intakes, preventing nutrient deficiencies, and preserving muscle and bone mass through resistance training with appropriate diet.37

The advisory also notes that although numerous practice guidelines recommend multicomponent nutritional and behavioral therapy for adults with obesity, using such therapy alongside GLP-1 medicines is not widespread.37

How Much Protein?

A 2025 narrative review on supplementation during GLP-1 treatment cites a daily protein intake target of 1.2 to 2.0 g per kg of body weight, and reports that whey protein combined with resistance training can help preserve lean body mass during weight loss, with additional strength benefits described for creatine monohydrate and beta-hydroxy beta-methylbutyrate.39

The review also addresses multivitamins for micronutrient insufficiency, and fiber and probiotics for bowel regularity and side effect mitigation.39

Conflict of interest, stated plainly: All four authors of that review are employed by GNC Holdings, a supplement retailer. The recommendations may still be sound. The commercial interest belongs next to them, and the joint society advisory above is the less conflicted source on the same questions.

Alcohol and Other Substances

Does Semaglutide Reduce Drinking?

A 2025 phase 2 randomized trial in JAMA Psychiatry tested this directly. It randomized 48 non-treatment-seeking adults with alcohol use disorder to nine weeks of semaglutide, escalated from 0.25 mg to 0.5 mg to 1.0 mg weekly, or placebo.40

Results split by measure. In a laboratory self-administration task, semaglutide reduced grams of alcohol consumed and peak breath alcohol concentration, with medium to large effect sizes. Weekly alcohol craving fell, as did drinks per drinking day, and the treated group showed greater reductions in heavy drinking over time.40

Two measures did not move. Average drinks per calendar day and number of drinking days were unaffected.40

In a subgroup who smoked, semaglutide predicted greater relative reductions in cigarettes per day.40

The authors described this as initial prospective evidence justifying larger trials. Forty-eight participants over nine weeks at sub-therapeutic weight-loss doses is a starting point, not a conclusion.

Eligibility

Who Are the Approved Products For?

Approval is by product and indication, not by the molecule.

The manufacturer states that Wegovy injection 1.7 mg or 2.4 mg and Wegovy tablets 25 mg are for reducing the risk of major cardiovascular events in adults with known heart disease and either obesity or overweight, and for helping adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose weight and keep it off. Wegovy injection is also indicated for children aged 12 and over with obesity.38

Two further indications are current and are missing from that summary. Wegovy injection at 7.2 mg, approved 19 March 2026 as Wegovy HD, is indicated to reduce excess body weight and maintain weight reduction long-term in adults with obesity, or overweight with at least one weight-related condition.45 Wegovy injection has been approved since 15 August 2025 to treat MASH in adults with moderate to advanced fibrosis, granted breakthrough therapy designation and cleared under the accelerated approval pathway.46

The MASH approval is why the ESSENCE trial described earlier is no longer only a trial result. Accelerated approval rests on a surrogate endpoint, here liver histology, and the trial continues to 240 weeks to establish whether the improvements translate into fewer deaths, transplants and liver-related events.46

Ozempic and Rybelsus are for improving blood glucose in adults with type 2 diabetes alongside diet and exercise, with additional cardiovascular and, for Ozempic, kidney indications.38

What Did the Trials Require for Entry?

STEP 1 enrolled adults with a BMI of 30 or above, or 27 or above with at least one weight-related coexisting condition, and without diabetes.1 SELECT required age 45 or older, existing cardiovascular disease, a BMI of 27 or above, and no diabetes.7 STEP TEENS enrolled ages 12 to under 18 with a BMI at or above the 95th percentile, or the 85th percentile with a weight-related condition.5

Trial entry criteria are not prescribing criteria. They describe who the evidence covers, which is a different question from who can be prescribed the drug.

Who Should Not Take It?

The manufacturer states these products should not be used by people who, or whose family members, have had medullary thyroid carcinoma, or who have multiple endocrine neoplasia syndrome type 2, or who have had a serious allergic reaction to semaglutide or any ingredient in the product.38

The manufacturer also advises stopping Wegovy two months before a planned pregnancy, and telling all healthcare providers about use before any procedure involving anaesthesia or deep sedation.38

How Good Is the Evidence

Who Funded It

Cochrane recorded that 17 of the 18 randomized trials it reviewed reported a major manufacturer role in design, conduct, analysis or writing, and named this an important concern about conflicts of interest.6

The Cochrane review itself was funded by the World Health Organization, which is why it carries weight the individual trials do not.

What Is Certain and What Is Not

Cochrane certainty ratings, medium-term follow-up:

Weight loss is the most certain finding. Everything downstream of it carries more doubt than the headlines suggest.

What Remains Unstudied

Long-term data rest on a narrow base. Cochrane's long-term analysis drew on two studies at 26 months.

Cochrane identified 46 ongoing trials and stated that underrepresented populations remain understudied.6 The eye signal is unresolved. The liver trial is unfinished. The 7.2 mg dose has a single trial behind it. No taper protocol has been tested. No trial has defined or tested a response to a weight loss plateau.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Paywalled. pubmed.ncbi.nlm.nih.gov/33567185

2. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. Open access. pubmed.ncbi.nlm.nih.gov/33755728

3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. Open access. pubmed.ncbi.nlm.nih.gov/35441470

4. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13(11):949-963. Paywalled. pubmed.ncbi.nlm.nih.gov/40961952

5. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). N Engl J Med. 2022;387(24):2245-2257. Open access. pubmed.ncbi.nlm.nih.gov/36322838

6. Bracchiglione J, Meza N, Franco JV, et al. Semaglutide for adults living with obesity. Cochrane Database Syst Rev. 2025;10(10):CD015092. Funded by the World Health Organization. Full text open from October 2026. pubmed.ncbi.nlm.nih.gov/41161683

7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. Paywalled. pubmed.ncbi.nlm.nih.gov/37952131

8. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. Paywalled. pubmed.ncbi.nlm.nih.gov/38785209

9. McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). N Engl J Med. 2025;392(20):2001-2012. Paywalled. pubmed.ncbi.nlm.nih.gov/40162642

10. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). N Engl J Med. 2025;392(21):2089-2099. Paywalled. pubmed.ncbi.nlm.nih.gov/40305708

11. Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE). Lancet. 2025;405(10489):1580-1593. Paywalled. pubmed.ncbi.nlm.nih.gov/40169145

12. Davies MJ, van der Meer P, Verma S, et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM). Lancet Diabetes Endocrinol. 2025;13(3):196-209. Paywalled. pubmed.ncbi.nlm.nih.gov/39848268

13. Bliddal H, Bays H, Czernichow S, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (STEP 9). N Engl J Med. 2024;391(17):1573-1583. Paywalled. pubmed.ncbi.nlm.nih.gov/39476339

14. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. Paywalled. pubmed.ncbi.nlm.nih.gov/40353578

15. Ciudin A, Sapin H, Fan L, et al. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis. Adv Ther. 2026;43(5):2090-2105. Open access. pubmed.ncbi.nlm.nih.gov/41820778

16. Drucker DJ. The expanding landscape of GLP-1 medicines. Nat Med. 2026;32(1):47-57. Paywalled. pubmed.ncbi.nlm.nih.gov/41482564

17. Jara M, Norlin J, Kjær MS, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31(9):3128-3140. Open access. pubmed.ncbi.nlm.nih.gov/40691365

18. Overgaard RV, et al. Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg. Diabetes Obes Metab. 2026;28(7):5982-5991. Open access. pubmed.ncbi.nlm.nih.gov/42023428

19. Kadowaki T, Heftdal LD, Ko HJ, et al. Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes (OASIS 2). JAMA Intern Med. 2025;185(10):1206-1217. Paywalled. pubmed.ncbi.nlm.nih.gov/40758358

20. Natividade GR, Spiazzi BF, Baumgarten MW, et al. Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis. JAMA Ophthalmol. 2025;143(9):759-768. Full text open from August 2026. pubmed.ncbi.nlm.nih.gov/40810985

21. Heberer K, Bress AP, Cogill S, et al. New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes. JAMA Ophthalmol. 2026;144(3):259-264. Open access. An erratum to Figure 2 was published in June 2026. pubmed.ncbi.nlm.nih.gov/41678180

22. Salama S, Omer EOE, Mahmoud A, et al. GLP-1 Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap. Cureus. 2026;18(4):e108005. Open access. pubmed.ncbi.nlm.nih.gov/42220875

23. Anyiam O, et al. How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis. Obes Rev. 2025 Jul. Open access. pubmed.ncbi.nlm.nih.gov/40181228

24. Nieto LM, et al. Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis. Am J Gastroenterol. 2026;121(2):424-431. Paywalled. pubmed.ncbi.nlm.nih.gov/40358430

25. Robalino Gonzaga E, Farooq A, Mohammed A, et al. Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting. J Clin Med. 2024;13(18):5403. Open access. pubmed.ncbi.nlm.nih.gov/39336890

26. Di Stefano R, et al. GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports. Diabetes Metab Syndr. 2025 Apr. Free article. pubmed.ncbi.nlm.nih.gov/40388845

27. Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27(Suppl 2):66-88. Open access. pubmed.ncbi.nlm.nih.gov/40196933

28. Quarenghi M, Capelli S, Galligani G, et al. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies. J Clin Med. 2025;14(11):3791. Open access. pubmed.ncbi.nlm.nih.gov/40507553

29. Lambert F, Guillon E, Gatta-Cherifi B, et al. Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study. Diabetes Obes Metab. 2026;28(1):443-451. Open access. pubmed.ncbi.nlm.nih.gov/41153084

30. Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study. BMJ Open. 2024;14(4):e083550. Open access. pubmed.ncbi.nlm.nih.gov/38663923

31. Austregésilo de Athayde De Hollanda Morais B, Martins Prizão V, de Moura de Souza M, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. J Diabetes Complications. 2024;38(10):108834. Paywalled. pubmed.ncbi.nlm.nih.gov/39178623

32. Scheltens P, Atri A, Feldman HH, et al. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease. Alzheimers Dement (N Y). 2026;12(1):e70200. Open access. pubmed.ncbi.nlm.nih.gov/41522368

33. Alsuwailem OA, Alanazi R, Almutairi HM, et al. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025;17(9):e92454. Open access. pubmed.ncbi.nlm.nih.gov/41111833

34. Haykal D, Hersant B, Cartier H, Meningaud JP. The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health. J Cosmet Dermatol. 2025;24(2):e16716. Open access. pubmed.ncbi.nlm.nih.gov/39645647

35. Calvarysky B, Dotan I, Shepshelovich D, Leader A, Diker Cohen T. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024;47(5):439-451. Open access. pubmed.ncbi.nlm.nih.gov/38273155

36. Al-Soleiti M, Leung JG, Mubaydeen T, et al. Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review. J Clin Psychopharmacol. 2025;45(6):613-618. Open access. pubmed.ncbi.nlm.nih.gov/40999647

37. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Lifestyle Med. 2025. Open access. Also published in Am J Clin Nutr. 2025;122(1):344-367 and Obesity (Silver Spring). 2025;33(8):1475-1503. pubmed.ncbi.nlm.nih.gov/40452753

38. Novo Nordisk Inc. Product safety information for Wegovy, Ozempic and Rybelsus, as published in the company's 24 February 2026 announcement. Manufacturer source. prnewswire.com

39. Johnson BVB, Milstead M, Kreider R, Jones R. Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review. Obes Pillars. 2025;16:100209. Open access. All authors are employed by GNC Holdings, LLC. pubmed.ncbi.nlm.nih.gov/41368199

40. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. Open access. pubmed.ncbi.nlm.nih.gov/39937469

41. Abedi MM, Patni MM, Shajahan ANB, et al. GLP-1 Receptor Agonists, Fertility Restoration, and Reproductive Safety in Women of Reproductive Age: A Narrative Review. J Clin Med. 2026;15(9):3204. Open access. pubmed.ncbi.nlm.nih.gov/42122936

42. Voros C, Chatzinikolaou F, Papapanagiotou I, et al. A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms. Int J Mol Sci. 2026;27(2):759. Open access. pubmed.ncbi.nlm.nih.gov/41596408

43. Yabut JM, Drucker DJ. Glucagon-like peptide-1 medicines and cancer. Nat Cancer. 2026;7(2):260-271. Paywalled. pubmed.ncbi.nlm.nih.gov/41545715

44. Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. 2025;135(21):e194751. Open access. pubmed.ncbi.nlm.nih.gov/41178710

45. US Food and Drug Administration. FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide. Press announcement, 19 March 2026. Approval of Wegovy HD 7.2 mg. fda.gov

46. US Food and Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as MASH. Published 15 August 2025. Wegovy injection approved for MASH with moderate to advanced fibrosis under the accelerated approval pathway, with breakthrough therapy designation. Interim results at week 72 in 800 participants: MASH resolution without worsening fibrosis in 63 percent against 34 percent, fibrosis improvement without worsening MASH in 37 percent against 22 percent. Trial continues to 240 weeks. fda.gov

47. US Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist Medications. Drug Safety Communication, 13 January 2026. Affects Saxenda, Wegovy and Zepbound. fda.gov

Not Medical Advice

A large evidence base is not a recommendation, and a result observed in a trial population may not transfer to any individual. Consult a qualified healthcare provider before acting on anything here.

Regulatory status re-verified against FDA sources 11 August 2026. Evidence counts last retrieved 2026-07-23 from PubMed and ClinicalTrials.gov. Literature review conducted 2026-08-03